IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v17y2020i16p5919-d399250.html
   My bibliography  Save this article

Prescribing Behavior of General Practitioners for Generic Drugs

Author

Listed:
  • Berna Tuncay

    (Department of Economics, Koc University, 34450 Istanbul, Turkey)

  • Sergio Pagano

    (Department of Physics, University of Salerno, 84084 Salerno, Italy)

  • Mario De Santis

    (Consorzio Mega Ellas, 84132 Salerno, Italy)

  • Pierpaolo Cavallo

    (Consorzio Mega Ellas, 84132 Salerno, Italy
    Istituto Sistemi Complessi del Consiglio Nazionale delle Ricerche (ISC-CNR), 00185 Rome, Italy)

Abstract

The factors influencing General Practitioners’ (GPs) prescribing behavior are diverse in terms of health care policies and regulations, GPs’ education and experience, demographic trends and disease profiles. Thus, it can be useful to analyze the specific local patterns, as they affect the quality of healthcare and the stability of the healthcare market. The aim of the present longitudinal retrospective study is to investigate the prescription of generic drugs in a database of about 4.6 million prescriptions from a sample of 38 GPs practicing in Salerno, Italy, within a timeframe of 15 years, from 2001 to 2015. The GPs in our study show a general tendency to increase prescriptions of generic drugs during the studied time span, to fulfill regulatory obligations and with some differences in prescription behavior according to age, gender and experience. The generics prescription depends also on the different diagnoses, with some diagnostic areas showing a greater generic drug prescription rate. Expanding this research to larger datasets would allow deepening the knowledge of the patterns of GPs’ prescribing decisions, to provide evidence to be used in comparison between different national settings.

Suggested Citation

  • Berna Tuncay & Sergio Pagano & Mario De Santis & Pierpaolo Cavallo, 2020. "Prescribing Behavior of General Practitioners for Generic Drugs," IJERPH, MDPI, vol. 17(16), pages 1-13, August.
    • Handle: RePEc:gam:jijerp:v:17:y:2020:i:16:p:5919-:d:399250
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/17/16/5919/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/17/16/5919/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Judith K. Hellerstein, 1998. "The Importance of the Physician in the Generic Versus Trade-Name Prescription Decision," RAND Journal of Economics, The RAND Corporation, vol. 29(1), pages 108-136, Spring.
    2. Zerbini, Cristina & Luceri, Beatrice & Vergura, Donata Tania, 2017. "Leveraging consumer’s behaviour to promote generic drugs in Italy," Health Policy, Elsevier, vol. 121(4), pages 397-406.
    3. Rodríguez-Calvillo, Javier A. & Lana, Alberto & Cueto, Antonio & Markham, Wolfgang A. & López, Maria Luisa, 2011. "Psychosocial factors associated with the prescription of generic drugs," Health Policy, Elsevier, vol. 101(2), pages 178-184, July.
    4. Fabiano, Valentina & Mameli, Chiara & Cattaneo, Dario & Delle Fave, Antonella & Preziosa, Alessandra & Mele, Giuseppe & Clementi, Emilio & Zuccotti, Gian Vincenzo, 2012. "Perceptions and patterns of use of generic drugs among Italian Family Pediatricians: First round results of a web survey," Health Policy, Elsevier, vol. 104(3), pages 247-252.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Costa-Font, Joan & Rudisill, Caroline & Tan, Stefanie, 2014. "Brand loyalty, patients and limited generic medicines uptake," Health Policy, Elsevier, vol. 116(2), pages 224-233.
    2. Brekke, Kurt R. & Konigbauer, Ingrid & Straume, Odd Rune, 2007. "Reference pricing of pharmaceuticals," Journal of Health Economics, Elsevier, vol. 26(3), pages 613-642, May.
    3. Daniel Burkhard & Christian P. R. Schmid & Kaspar Wüthrich, 2019. "Financial incentives and physician prescription behavior: Evidence from dispensing regulations," Health Economics, John Wiley & Sons, Ltd., vol. 28(9), pages 1114-1129, September.
    4. Hassali, Mohamed Azmi & Wong, Zhi Yen & Alrasheedy, Alian A. & Saleem, Fahad & Mohamad Yahaya, Abdul Haniff & Aljadhey, Hisham, 2014. "Perspectives of physicians practicing in low and middle income countries towards generic medicines: A narrative review," Health Policy, Elsevier, vol. 117(3), pages 297-310.
    5. Khaled Bennour, 2007. "Advertising and Entry Deterrence: How the Size of the Market Matters," International Journal of Business and Economics, School of Management Development, Feng Chia University, Taichung, Taiwan, vol. 6(3), pages 199-206, December.
    6. Frank, Richard G. & Zeckhauser, Richard J., 2007. "Custom-made versus ready-to-wear treatments: Behavioral propensities in physicians' choices," Journal of Health Economics, Elsevier, vol. 26(6), pages 1101-1127, December.
    7. Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
    8. Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2014. "Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark," Journal of Health Economics, Elsevier, vol. 36(C), pages 174-187.
    9. David Granlund & Niklas Rudholm, 2012. "The Prescribing Physician’s Influence on Consumer Choice Between Medically Equivalent Pharmaceuticals," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 41(3), pages 207-222, November.
    10. Brekke, Kurt Richard & Holmås, Tor Helge & Straume, Odd Rune, 2013. "Margins and market shares: Pharmacy incentives for generic substitution," European Economic Review, Elsevier, vol. 61(C), pages 116-131.
    11. Paraponaris, A. & Verger, P. & Desquins, B. & Villani, P. & Bouvenot, G. & Rochaix, L. & Gourheux, J. C. & Moatti, J. P. AU -, 2004. "Delivering generics without regulatory incentives?: Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names," Health Policy, Elsevier, vol. 70(1), pages 23-32, October.
    12. Granlund, David & Sundström, David, 2018. "Physicians prescribing originals causes welfare losses," Economics Letters, Elsevier, vol. 170(C), pages 143-146.
    13. Sacks, Daniel W., 2018. "Why do HMOs spend less? Patient selection, physician price sensitivity, and prices," Journal of Public Economics, Elsevier, vol. 168(C), pages 146-161.
    14. Attema, Arthur E. & Galizzi, Matteo M. & Groß, Mona & Hennig-Schmidt, Heike & Karay, Yassin & L’Haridon, Olivier & Wiesen, Daniel, 2023. "The formation of physician altruism," Journal of Health Economics, Elsevier, vol. 87(C).
    15. Leemore Dafny & Christopher Ody & Matt Schmitt, 2017. "When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization," American Economic Journal: Economic Policy, American Economic Association, vol. 9(2), pages 91-123, May.
    16. Sara Fisher Ellison & Christopher M. Snyder, 2010. "Countervailing Power In Wholesale Pharmaceuticals," Journal of Industrial Economics, Wiley Blackwell, vol. 58(1), pages 32-53, March.
    17. Aysegul Timur & Gabriel Picone & Jeffrey DeSimone, 2011. "Has the European union achieved a single pharmaceutical market?," International Journal of Health Economics and Management, Springer, vol. 11(4), pages 223-244, December.
    18. Makoto Kakinaka & Ryuta Kato, 2013. "Regulated medical fee schedule of the Japanese health care system," International Journal of Health Economics and Management, Springer, vol. 13(3), pages 301-317, December.
    19. Susana Narciso, 2005. "Retailing Policies for Generic Medicines," International Journal of Health Economics and Management, Springer, vol. 5(2), pages 165-190, June.
    20. Dalen, Dag Morten & Sorisio, Enrico & Strøm, Steinar, 2009. "Choosing among Competing Blockbusters: Does the Identity of the Third-party Payer Matter for Prescribing Doctors?," Memorandum 10/2009, Oslo University, Department of Economics.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:17:y:2020:i:16:p:5919-:d:399250. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.